A filing from ProShares indicates it has ambitious plans for some of the market’s most popular hot spots. The paperwork outlines 20 inverse and leveraged funds covering four key areas: the China A-shares market, MLPs, cyber security and pharmaceuticals.
Each suite of five funds will include an UltraPro (3x), an Ultra (2x), an Ultra Short (-2x), a Short (-1x) and an UltraPro Short (-3x) ETF, as shown below:
- ProShares UltraPro China A Shares
- ProShares Ultra China A Shares
- ProShares Short China A Shares
- ProShares UltraShort China A Shares
- ProShares UltraPro Short China A Shares
- ProShares UltraPro MLP
- ProShares Ultra MLP
- ProShares Short MLP
- ProShares UltraShort MLP
- ProShares UltraPro Short MLP
- ProShares UltraPro Cyber Security
- ProShares Ultra Cyber Security
- ProShares Short Cyber Security
- ProShares UltraShort Cyber Security
- ProShares UltraPro Short Cyber Security
- ProShares UltraPro Pharmaceuticals
- ProShares Ultra Pharmaceuticals
- ProShares Short Pharmaceuticals
- ProShares UltraShort Pharmaceuticals
- ProShares UltraPro Short Pharmaceuticals
While the pharmaceuticals ETFs will be tied to the S&P Pharmaceuticals Select Industry Index, the rest of filing did not specify indexes for the other categories. All four areas have recently either seen very successful ETF launches, such as in the case of the $1.1 billion PureFunds ISE Cyber Security ETF (HACK | C-31), or enjoyed a great deal of investor attention in the markets.
The filing did not include tickers or expense ratios.
AdvisorShares Closes DBIZ
Yesterday, AdvisorShares shuttered its AdvisorShares Pring Turner Business Cycle ETF (DBIZ); the fund’s last day of trading was Friday, Oct. 2.
DBIZ was an actively managed fund that relied on technical, fundamental and business cycle analysis and used a sector rotation approach. It could invest in equities and fixed income, including via other ETFs. The fund came with a rather hefty expense ratio of 1.68 percent.
When it closed, the fund had less than $5 million in assets under management.
Contact Heather Bell at [email protected].